The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Pfizer plans to explore other obesity treatments for testing. Pfizer is halting the development of its potential pill for treating obesity following an injury that happened during a clinical trial.

Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at ... the company also tried to belay its image as a pharma monster, like many others in the industry, by ...

(Funded by Pfizer; ClinicalTrials.gov number, NCT03307980.) Supported by Pfizer. Disclosure forms provided by the authors are available with the full text of this article. We thank Crystal Austin ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $125.5 billion, the company ...

In another sign of the challenges facing gene therapy developers, Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

Healthcare & Pharmaceuticalscategory· April 14, 2025 Pfizer ends development of weight-loss pill danuglipron Pfizer said on Monday it has discontinued development of experimental weight-loss pill ...

The pharmaceutical industry faces environmental challenges. Green chemistry offers sustainable solutions to reduce waste and enhance drug discovery processes.